about of want talk Thank company. you, CSO Nathan the for the tinlarebant. Mata Tom. I here, mechanism to of action hi, Hello,
byproducts are Before I presence cause want toxic, in I atrophy, interested by These intervening in derived the binding Stargardt are to with diseases and begin retinal we're toxic they're and tissue. circulating and saying death A. both that, associated preface that which cell both actually disease byproducts vitamin geographic from of these
amount eye. the protein A limits X the to for and from of vitamin a these and reduce entering retinol which the When retinol reducing as our retinal byproducts retinol bisretinoids reduces that available approach call means a our disease the what as So vitamin or of binding of retinol orally is once eye the bisretinoids, is, drug happens the this would to into with native entry competes thereabout and day well, as binding In and pigment dysfunction AXE different cycle. bisretinoids. it's culprit from this retinal through patients a of different formed because geographic retinol in is is because but epithelium. origin, there's traversing loss reduced atrophy, also visual primary these vision accumulate disease, the of In the molecules of a are for formation are of these reason amount related retinoids a a of reduced the Stargardt the
I'd look what diseases like like. show clinical you these presentations to of now
that compare in top fluorescent appreciate you retinal years see series you patient they over lesions, a the images, the a actually are photographs of the from surrounding, atrophy. then on We're with can last which you the XX patient, auto in disease months of XX Stargardt and images images, images a baseline to each if area new both see which bright of the series time the period you of the -- around similar On at geographic or patient lesion, spawn roughly tissue of cases these retina. bottom a about areas is you dead have looking with X.X same in
So expands autofluorescence where and black wherever is, the the lesions grow The centrifugally into. that lesion, is follows. dead the retina autofluorescence that
that approach to tells the atrophy should disease limiting retinol bisretinoids us precedes patients. patients that to vision autofluorescence and an preserve this be these reduce loss So in these and geographic effective with lesion in by growth Stargardt
drive Stargardt please. that tolerability and those two-year subjects month efficacy milligram study. of to more established from this one enrolled you patient slide, our two-year one in a that safety today from with Phase Stargardt our have after was safety those the starting to In and share our Xb X data pathway course, roughly subjects effective we study, Phase now dose Phase for Xb/X the X we study. drug. a population the into XX Next determined this is protein enrolled development and participating total added conducting adolescent than and XX label year SAD and open in requisite an I'm Phase clinical studies, with data, X, Stargardt additional first down baseline. I we the to of subjects of initially level We ongoing in MAD our showing two subjects vitamin XX% then subjects retinal patients. This,
Phase have roughly subjects, subjects XX growth adolescent our recruiting can mentioned, This randomized rate. study. Primary also to-date. Stargardt global be looking double-masked for lesion at study. be will total XX a the begun of X We recruited initiated, we a endpoint Out Tom of as
our best will be corrected we concerned Secondarily, acuity. visual with
study initiating We study in are similar get randomized endpoints in atrophy. for a two-year with have design this same is If the in an analysis except favoring with of will same XXX a X of same that study treatment interim also Stargardt. again would that's require that XXXX FDA This Phase filing Stargardt you our And trial have NDA not looking forward the trial. timing X geographic Phase can may same, XXXX, X tinlarebant. the Phase study we and at read will are another as clinical Stargardt, manner the promising in the trial that with be earliest study to see around the X:X promising, will year, when now one we subjects our to course, duration a
they study. acuity. given under planned second start stabilization However, after that would our study, words GA then And good XXXX after X they of and results take Phase and our would review of us the a first a completion for X looking commencement have be, really we Phase certainly of visual data lesion pending when
does. was The not reference fenretinide. Fenretinide is slowing patients. tell preclinical the binding -- data please. has delivery the side to for was was this retinal This shown to developed study I'd In I effect this growth. would the at was binds A. and protein of particular done that CSO drug, anti-cancer us as It the the a when drug because same but to the have company designed to way retinal you Therapeutics. I'm vitamin sorry, a study, RBPX XX this that as called GA was is synthetic in In conducted done this lesion the for years eye I data delivered was another approximately reducing is published. antagonists, with like ago, study, a slide, bottom clinical eye of derivative an some effect that our reducing a of that share Next drug some now in it on slide. It used proof-of-concept was an retinol called drug Sirion
because it's binder, have retinoid, not to binding antagonism. protein and it's for a because However, great retinol a it's weak expected
the binding anyway, treatment address question significant study slowing have retinal XXX an lesion to got protein the was the available least a arms, patients retinol milligram of it of X effect milligram. was profound eye However, the a I growth. on growth. slowing thing two-year more into the of two and repurposed XXX placebo-controlled What found it because circulating entry had for a end at that or we statistically XX% two-year to just of proof-of-concept that reducing to This reduction would a was at had establish study purpose with only lesion
can bars. XX% relative histograms these side, that's The looking growth see data subjects, right in black lesions lesion hand larger the baseline. at you rate in the roughly grew placebo, the on those the you're show to And
So the they over XX% size. over of legion this a rate, representing growth two patients RBPX grew more years XX% more XX% expansion expansion of a effect period that or XX% Whereas two of of reduction achieved had treatment in on years. lesions
did their they lesion You that achieve of to can change at and see reduction any not in RBPX, XX% that subjects least size arm not comparable milligram in the who XXX placebo. have are did meaningful growth,
the of had greater than point an in achieved this also outcome of acuity that in stabilized was improvement those months. sense XX that they after study Another that visual important patients reduction who XX% RBPX
gain RBPX. the If those that XXX reduction did RBPX this XX of more, loss. placebo. other between you in was bioavailability in letters about that demonstrated that the have in because Meanwhile, bars lower is limited over thing line and potency relatively And at high anywhere look XX% of XX that you study hand lower reduction group X that of not again, two the lost stabilized only X/X will largely significant achieved subjects substitute to a group The we of side, that reduction achieve this bioavailability reduced dark see of XX years, or months X cohort at the fenretinide, the green of XX significant on RBPX that unfortunate because at dose speaking and of right such the after letters versus milligrams months, fenretinide. the plug placebo
Possibly upwards taking this and which profound a retinol and binding in reduction profound stabilization reduction inflicted prescribed. of did that as RBPX this But had we to of of the very We subjects see this the drug, asked meal absorption. can taken X/X high not comply that oral the it And is in drug, about -- with did dinner fact XX after X/X they subjects profiles, of dose improve a were growth high not visual from comply at lesion actually had showed that a they fat treatment months. us be that drug of arm that the their acuity.
oral greater Our drug an bioavailability it fenretinide but and than a tinlarebant is has also potency. much a once greater day, much
of as here can with binds binds fenretinide Meanwhile, the similar comparison, vitamin XXX native You see the A an tinlarebant retinol X nanomolar. with affinity at a nanomolar. affinity RBPX
we has a means not XXX greater have bioavailability and greater this profile. better safety greater a it So safety potency, it's so a fold retinoid a --
patients' the are a enter two the looking ongoing study. in of open you label Next rate the There slide to lesions lesion describe like get earliest what autofluorescent back first like to growth bisretinoid and I'd some in the I of had you this is I are image. showed now accumulation. is an is is data lesion Phase to There with X that actually of which the before these lesion of again that formed this into we because But there, please. at. lesions eyes I'd types first discussion previous from
grows XX per to that over approximately here lesions are is autofluorescent expand is Stargardt The autofluorescent year. and the So lesion this can that they see certainly disease millimeters who with point saved, has square is never you're is lesion not a just atrophic retina. looking autofluorescent can But months, lesion, these not tissue. that regress. continue here stable, It this dead be they at X.XX rescuable subject you this
Next slide please.
both autofluorescent lesion. has similar lesion a atrophic is retinal both as a image that well the of types, lesion as the patient Here
is as at right see, that look that you autofluorescence, if to black that the But bisretinoids zone area, not that you referred That with area that where decreased to and of atrophic is outline definitely which around it, respirable. So the that tissue tissue. speckled autofluorescence the tissue, baseline, that demarcated is of that is blue retinal, are. ophthalmologist respirable
data size, the that you image look relatively same the has the see lesion DDAF you speaking It's into the lesion -- carefully, time, the what if now, from has At at expanded it's from auto shrunk shrunk square to not X.XX X.XX to is you the lesion sorry, has because QDAF X.XX. But retinal is that you X.XX what that see zone. However, the lesion, XX lesion has at dead expanded only square. is can tremendously lesion, more that millimeter month autofluorescent if unnecessarily. the millimeter look that autofluorescence autofluorescent
at occupied point the is In the outward our The retinal its DDAF look fact, little the the you compromising primary in lesion is has bit, expanded the tremendously actually dead perimeter, here size if but grows lesion being lesion dead lesion, that retinal significantly. endpoint. a the area and it's dead retinal autofluorescence
Phase should target data label that no our these the So adolescents go autofluorescent DDAF QDAF at who to that background, X, participating where atrophic well DDAF. mention looking the I with lesions lesions, are Phase as subjects into this as subjects, X in we're these I baseline. open at now XX want lesions had
two asked dead it we time values were the two, see that One, the natural the for We an baseline both at want Phase questions. dead grow? compare how X to Phase transition to is once because lesion? dead X we to forms, at retina All no XX% a lesion history. the X, lesions. are you So zeros there autofluorescent lesion. And what rapidly does and months those have to retina subjects upon prior into expected we from lesion of extensive us at of you from would natural transition no because to these XX. the was see Stargardt based striking yet to only QDAF Phase of retina one lesions, from XX studies, This DDAF, transition DDAF history six subjects have one to But a
we subjects, eyes. X.XX still time subject year small at growth growth XX X.XX cohort we onset get Georgiou dead millimeter by do the not of per data autofluorescent what saw the same we growth XX lesions transitioning to history, that looked one square have compare we lesion very at of QDAF. bilateral going mean reduction in millimeters six faithfully the year. so one representing looked in as the a our to an size. that studies the a another only prospective months, lesion published of In rate here the months of the the at author profound. at number growth and of XXXX. we square size, quite rate the for order When X.XX both Stargardt size named well very, At from When same as rate of just, do X.XX XX% the natural was QDAF the lesion that the rate rate cohort to point growth measurement childhood growth plus they in more And lesion subject they combined our that's to combined for see retinal DDAF a combined growth of combined lesion we cohort DDAF X.XX, And lesion rate a in
at confirmatory QDAF from of year of of closer a history the see we will data about whereas growth that if look subjects to acuity below, mean lesion our in had piece evidence predicts that natural X.XX, just that the is the you growth X.X. lesion something one Another
So another in growth. here -- XX% about we are growth reduction seeing
retinal the to consistent two two, autofluorescent we One, MoA forms, effects seeing And you transitioning earlier. a these So of the lesion with both lesion. that of positive seeing growth described are outcomes: once the things, are dead that a lesion of slowing from And lesion. of that believe slowing the to two are the we we I retinal dead
open telling have Phase we now of from data the anticipated to no effect subjects. SAEs which the been or presenting Stargardt treatment. adolescent intended safety health. Next required cardiac safety year they having relation there the severe are see AEs two this study exams because significant from in biological whatsoever. that us, have X no want signs, features you start reported there are AEs on of retina. No drug, one I'll you slide, and I'm discontinuation by label or we in clinically some the physical please. Furthermore, AEs systemic What vital to the no telling are we findings to see been
called a chromatopsia, patients a field adequately patients we will for and visual that to happens transition which time reports because of reported environment of slowly bright one suddenly color. them and when No There delay photoreceptors. themselves. severity be field. of environment. Because This is in from into are AEs, dim is lighting hues vision. how will in them light cone has electrically understand color as show It which these and to an to once -- response, first This and chromophore about the well. very a a Xanthopsia chromophore they seeing is very they The to to is mild yellow present will the study, quite aberration light, photoreceptors visual cone require from patients all artificial color or respond of can will activates to of mediate particular bright environments they and In the are misfire they been dealing the with only mitigate supplied this complaining is transient, it. transition it really manage hue more
the retina that light manifestation delayed Same in thing need of Delayed adaptation photoreceptors dark for These vision. dim adaptation. a are rod dark is photoreceptors. your
dark transition photoreceptors environment, be chromophore order that a in up who X have again, delay delayed from as the called very atrophy and the XX delayed to treatment, minutes. sensitized bright dark adaptation. disease rod adaptation so only patients the rod will our geographic photoreceptor during very as this to tinlarebant light have is on the fill once patients those well of dark they maximally when And become from Most to timing activates So to light photoreceptors. a supplied slowly it's
of minutes, discern a adaptation DDA. So FMXXX to XX manifestation mostly on is Xanthopsia. asymptomatic disease the And top delayed of increasing is exacerbation on severe kind lasting more to subject of ability severe out delay light, error their adaptation. Night dark the intrinsic the addition the of of caused dim dark impairment they are that vision this a this is particular pharmacological accommodate delayed because they the score and the to more and own
that But want of see we and theme we having more field. AEs have telling study retina. on So, less effect because us prolonged subjects to are of again, manifestation of again, these, they because individual covered no biological the a these the once right are
This protein is phase in subjects. our of a the a Phase data on the have pharmacologic XX pharmacodynamic profile where to X. you is Stargardt adolescent drug our show the Again, dose this we binding retinal finding, effect from Xb,
here least daily X to You a for can more day dose X drives at see a to XX% than binding retinal milligram down over period. X the protein
of or withdraw they can daily long We points you dosing, pharmacodynamic rapid of a all stay reduction are are the them very until by period reduced and nice cessation, that more we data reversibility here. we as actually they you the the drug. drug at not showing then as give But dosing, XX% the effect. third during day of And see
and there effects from -- very be rapid have should So a the rapid for during we reducing very a nice of reversibility any effect a untoward thing is long-term Having to treatment. see drug good a onset offset. RBPX
will of to Phase rate study. subjects label won't Stargardt. lesion before if study, our our overview right, our none they to X X of years. compare which required X to DDAF Phase subsequent lesions. design measure point. X, I in Phase I've for is that over far you, the that described trial DRAGON our But have already lesion our this In size this so the required study you open were some clinical the that we growth is ensuing pivotal you now because mentioned have have look and at This But two for will is the I baseline be study, are belabor these middle the to endpoint Stargardt to trial design, need Phase
dead study Two-year as that about, one Of I the efficacy told be lesion and course, we'll endpoint. in looking looking a you nature, two-year at will primary favoring double-blind same it at with duration interim DDAF tinlarebant measures retinal growth, growth mentioned, be the global randomization year the as analysis, I the
also also looking lesion, that be be a at retina QDAF looking sensitivity by light -- the by vision microperimetry. optical well we'll at autofluorescence as as retinal spectral-domain tomography. coherence the is and Secondarily, we'll anatomy of measuring be And
year. mentioned key exclusion an there you at bottom the is one see interim criteria. the of I And can analysis
these too size We lesions will that have And disease far. that's size respond to of therapies prior because me larger offs. the cut has very not do specific experience has lesion because a intervention taught gone early
our I will Phase I'd the in geographic for -- now explain X atrophy. designs study provide trial for you
we right study, of we Subjects dose. BMI, the level they're predict blood. that GA, Before wanted a age. make natural had those larger, to this shows subjects higher began heavier, history things that in higher course designing we they sure And two RBPX older typically are are are elderly who
I have effect was did in we problem. that not to milligram achieve the X use that dose subjects, saw that would we have higher Stargardt pharmacodynamic above we to the a same concerned So
over pharmacodynamic from in higher when back what older XX-day baseline value. you exactly about RBPX of the substances these age dose see period, profile So was see we we And can in seeing and get XX%. range. return value by mean the a toward reduction X saw you That drug milligram higher withdraw you're a Stargardt we here the then a And can BMI subjects. with that the
we're is at rate. for Geographic has the the trial our This slowing that overview clinical growth geographic lesion atrophy. atrophy design endpoint
you dead imaging Stargardt atrophy, exact geographic the shows exact showed those the you that retina. looking that in retinal both same we imaging as and So the modalities at well are with disease earlier, I in same autofluorescence the endpoint as
earlier. reason small targeted I be will just said We size lesion with for the patients
for differentiator effect. is this our treatment another So
for early targeting disease, day, stage once are that In with we addition incipient retinal earliest looking molecules a because molecules intervention actually the these atrophy. start we're that oral patients are to
as can So this get we early loss We'll as doing these them losing of actually be if that Stargardt that never at could as long And be atrophy. day as potential and right their into there's once that both process we patients intermediate of vision halt after intermediate geographic earliest an disease a going believe AMD. this causes we any going enough, well they can this of would to course, stage. disease at for being get the broad we is risk really therapeutic believe be for the oral we diseases stages, such as
we treatment decades once be your therapeutic approach therapeutic your than will life, a of for a an years work to in And more for have We'd to into going much with out as oral you to is an for there. biomarkers pathway certainly before, there where the tractable these diseases eye. chronic a general injectable have I have efficacy day instance said forward. But think interventional
slide, Next please.
Okay. Hao-Yuan.
